Progenitor cells of mesodermal lineage
AssigneeCell Therapy Limited
InventorsThomas Averell Houze, Martin John Evans, Ajan Reginald, Ina Laura Pieper
Life of this patent
Estimating the term…
Abstract
The invention relates to progenitor cells of mesodermal lineage and their use in therapy.
Claims24
An isolated population of progenitor cells of mesodermal lineage, wherein the cells (a) express detectable levels of CD29, CD44, CD73, CD90, CD105, CD271, CD120a (tumour-necrosis factor (TNF)-alpha Receptor 1), CD120b (TNF-alpha Receptor 2), CD50 (Intercellular Adhesion Molecule-3, ICAM-3), CD54 (ICAM-1), CD58 (Lymphocyte function-associated antigen-1, LFA-1), CD62E (E-selectin), CD62L (L-selectin), CD62P (P-selectin), CD106 (Vascular cell adhesion protein, VCAM-1), CD102 (ICAM-2), CD166 (Activated leukocyte cell adhesion molecule), CD104 (Beta 4 integrin), CD123 (Interleukin-3 Receptor), CD124 (Interleukin-4 Receptor), CD126 (Interleukin-6 Receptor), CD127 (Interleukin-7 Receptor) and fibroblast growth factor receptor (FGFR) and (b) do not express detectable levels of CD14, CD34 and CD45, and wherein at least 80% of the population comprises the progenitor cells of mesodermal lineage.
Dependencies are inferred from the claim text.